Drug Profile
Udonitrectag - MimeTech
Alternative Names: MT-8; Negermin lysine salt; REC 0/0559; REC-0559Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Universita degli Studi di Firenze
- Developer MimeTech; Recordati
- Class Anti-inflammatories; Antianaemics; Antiglaucomas; Cardiovascular therapies; Eye disorder therapies; Nerve growth factors; Neuroprotectants; Skin disorder therapies
- Mechanism of Action Apoptosis inhibitors; Autophagy inhibitors; Nerve growth factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Keratitis
- Phase I/II Diabetic foot ulcer
- Preclinical Choroideraemia; Dry eyes; Glaucoma; Lung transplant rejection; Myocardial infarction; Pressure ulcer; Reperfusion injury; Retinitis pigmentosa; Skin disorders; Varicose ulcer
- No development reported Sickle cell anaemia
Most Recent Events
- 19 Jul 2023 Preclinical trials in Varicose ulcer in Italy (unspecified route) (MimeTech pipeline, July 2023)
- 28 Mar 2023 Udonitrectag is still in preclinical development for Glaucoma in Italy (MimeTech pipeline, March 2023)
- 28 Mar 2023 Udonitrectag is still in preclinical development for Dry-eyes in Italy (MimeTech pipeline, March 2023)